Latest news with #FirstHalf

VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ...

Yahoo

3 days ago

Business
Yahoo

VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ...

Revenue: Over $400,000 in Q2 2025; first half total revenue over $650,000, up 15% year-over-year. Operating Expenses: Declined 9% in Q2 2025 compared to Q2 2024. Net Cash Used in Operating Activities: $6.3 million in Q2 2025, down from $6.7 million in Q2 2024. First Half Net Cash Used: $10.6 million, a 30% reduction from the prior year. Cash and Cash Equivalents: Approximately $2.3 million at the end of Q2 2025, down from $3.3 million at the end of 2024. Convertible Loan Note Proceeds: $6 million received in Q2 2025. Direct Offering Proceeds: $1.2 million received post-Q2 2025. Nu.Q NET Revenue: First revenue recorded for sales of the human product Nu.Q NET. Warning! GuruFocus has detected 5 Warning Signs with VNRX. Release Date: August 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points VolitionRX Ltd (VNRX) achieved a 15% increase in total revenue for the first half of 2025, with the first revenue recorded from sales of a human product, Nu.Q NET. The company successfully reduced total operating expenses by 22% and net cash used in operating activities by 30% compared to the previous year. VolitionRX Ltd (VNRX) is in active negotiations with over 10 companies for potential licensing agreements, with some discussions at the contract finalization stage. The Nu.Q platform has shown promising results in various clinical studies, including its use as a prognostic marker in non-small cell lung cancer and as a biomarker for sepsis. The company recorded its first revenue from sales of the CE Mark Nu.Q NETs automated product in Europe, with 11 hospital networks in five countries placing orders. Negative Points Revenues remain unpredictable and 'lumpy' at this early stage of commercialization, leading to a lack of revenue guidance for 2025. Cash and cash equivalents decreased to approximately $2.3 million at the end of the quarter, down from $3.3 million at the end of 2024. The company is dependent on executing licensing agreements with significant upfront payments to achieve its goal of being cash neutral for the year. The commercialization of the Nu.Q platform in the human diagnostic market is still in progress, with no finalized out-licensing deals yet. The regulatory path for some products, such as those requiring FDA approval, could take 2 to 3 years, delaying potential revenue streams. Q & A Highlights Q: Can you comment on which uses of the Nu.Q platform have been attracting the most attention from potential partners in the human health space? A: Cameron Reynolds, President, CEO, and Director, stated that there is significant interest across all areas of the Nu.Q platform. The Discover side has over 20 clients, including major companies. In NETosis, large diagnostic and autoimmune companies are engaged, with three working on their platforms. The oncology space has seen increased interest, particularly in lung screening programs and liquid biopsy companies. Overall, the platform's stability, low cost, and adaptability are attracting widespread attention. Q: Are you starting to see repeat customers as you're making some of the sales of Nu.Q NETs in Europe? A: Yes, Cameron Reynolds confirmed that multiple hospital networks have placed repeat orders, indicating satisfaction with the test's adaptability and performance. There is also a growing number of repeat orders in the Nu.Q Discover and Nu.Q NETs segments. Q: As you execute a deal and bring real capital into the company, how do you use that capital? A: Cameron Reynolds explained that the goal is to become revenue neutral. Each deal will vary, with some involving large payments and ongoing revenues. The capital will help drive revenues, particularly in the vet space, where automation of centralized labs is crucial for growth. Q: Could you provide some color on the indication or application of the first human deal? A: While specific details are confidential, Cameron Reynolds mentioned that all deals depend on the use of their robust and reproducible test. The deals will vary in size, with some involving smaller milestone payments and others larger ones, all providing ongoing revenue. Q: Could you provide some rough estimates as to the length of time required for your customers typically between licensing the deal to commercialization? A: Cameron Reynolds stated that timelines vary. For co-marketing in Discover, revenue can be immediate. In the vet space, it's quicker due to regulatory processes. For human applications, regulatory paths like CE Mark and FDA can take 2-3 years, with some processes already underway. Q: With the Taiwan screening program, are they prepared to scale that type of a program? A: Yes, Cameron Reynolds confirmed that the trials in Taiwan are on the final validation study, and the test is on the machine that would be used for launch. They are considering a mixed approach of clear lab and potential Taiwanese FDA approval for broader uptake. Q: Are there any other regulatory or guideline bodies in Taiwan that would need to sign off on using the test before it went into full production? A: Cameron Reynolds mentioned that the test is on the current machine, and the validation study is in process. If successful, it could be launched in a clear lab setting, generating direct sales revenue, with potential TFDA approval for broader use. Q: Regarding the lateral flow test for NETs, was that an internally developed platform or did you work with a partner? A: Cameron Reynolds stated that they worked with several partners on the lateral flow test, which performed well. They are exploring capillary blood testing and see potential for direct sales, especially in developing countries and for home testing. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data